Testosterone replacement therapy of opioid induced male hypogonadism improved body composition but not pain perception A double-blinded, randomized and placebo-controlled trial

2020 ◽  
Author(s):  
Dorte Glintborg ◽  
Vægter Henrik Bjarke ◽  
Christensen Louise Lehmann ◽  
Emma Bendix ◽  
Thomas Graven-Nielsen ◽  
...  
Keyword(s):  
Body Composition ◽  
Replacement Therapy ◽  
Pain Perception ◽  
Controlled Trial ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
Double Blinded

scholarly journals Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men

2009 ◽  
Vol 161 (3) ◽  
pp. 443-449 ◽  
Author(s):  
Atish Mathur ◽  
Christopher Malkin ◽  
Basil Saeed ◽  
R Muthusamy ◽  
T Hugh Jones ◽  
...  
Keyword(s):  
Body Composition ◽  
Replacement Therapy ◽  
Controlled Trial ◽  
Specific Antigen ◽  
Density Lipoprotein ◽  
Intima Media Thickness ◽  
Lipid Profiles ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Exercise Induced

IntroductionIn short-term studies, testosterone replacement therapy has been shown to protect male subjects from exercise-induced ischaemia and modify cardiovascular risk factors such as insulin resistance, fat mass and lipid profiles.MethodsThis randomised parallel group controlled trial was designed to assess the treatment effect of testosterone therapy (Nebido) compared with placebo in terms of exercise-induced ischaemia, lipid profiles, carotid intima-media thickness (CIMT) and body composition during 12 months treatment in men with low testosterone levels and angina.ResultsA total of 15 men were recruited but 13 (n=13) reached adequate duration of follow-up; seven were treated with testosterone and six with placebo. Testosterone increased time to ischaemia (129±48 s versus 12±18, P=0.02) and haemoglobin (0.4±0.6 g/dl versus −0.03±0.5, P=0.04), and reduced body mass index (−0.3 kg/m2 versus 1.3±1, P=0.04) and triglycerides (−0.36±0.4 mmol/l versus 0.3±1.2, P=0.05). The CIMT decreased in the testosterone group more than placebo, but full between group analyses suggested this was only a statistical trend (−0.5±0.1 vs −0.09±0.06, P=0.16). There were no significant effects on serum prostate specific antigen, total or high-density lipoprotein cholesterol; or on mood and symptom scores as assessed by Seattle Angina Score and EuroQol.ConclusionThe protective effect of testosterone on myocardial ischaemia is maintained throughout treatment without decrement. Previously noted potentially beneficial effects of testosterone on body composition were confirmed and there were no adverse effects.

scholarly journals Short term testosterone replacement therapy improves libido and body composition

2009 ◽  
Vol 53 (8) ◽  
pp. 996-1004 ◽  
Author(s):  
Edésio Seara de Andrade Júnior ◽  
Ruth Clapauch ◽  
Salo Buksman
Keyword(s):  
Body Composition ◽  
Waist Circumference ◽  
Replacement Therapy ◽  
Late Onset ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Efficacy And Safety ◽  
Short Term ◽  
Sf 36 ◽  
Late Onset Hypogonadism

OBJECTIVE: To assess the efficacy and safety of testosterone replacement in males with late-onset hypogonadism compared to hypogonadal men without replacement, and controls, during six months. METHODS: We assessed, through ADAM, AMS, IIEF-5 and SF-36 questionnaires, and through clinical and laboratorial examinations, 62 patients divided into three groups: 17 hypogonadal males (HR) used intramuscular testosterone every three weeks; 14 hypogonadal males (HV) and 31 non-hypogonadal males (CV) used oral vitamins daily. RESULTS: When compared to others, HR group obtained libido improvement assessed by ADAM 1 (p = 0.004), and borderline sexual potency improvement assessed by IIEF-5 (p = 0.053), besides a decrease in waist circumference after eight weeks (p = 0.018). The remaining parameters did not differ between the groups. PSA and hematocrit remained stable in those using testosterone. CONCLUSION: Six months of testosterone replacement improved sexuality and body composition, with prostatic and hematological safety.

scholarly journals A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures

2017 ◽  
Vol 2017 ◽  
pp. 1-7
Author(s):  
Suhaib Radi ◽  
Andrew C. Karaplis
Keyword(s):  
Bone Mass ◽  
Replacement Therapy ◽  
Fragility Fractures ◽  
Testosterone Replacement ◽  
Vertebral Compression Fractures ◽  
Testosterone Replacement Therapy ◽  
Male Hypogonadism ◽  
Mineral Density ◽  
Compression Fractures

While the contributing role of testosterone to bone health is rather modest compared to other factors such as estradiol levels, male hypogonadism is associated with low bone mass and fragility fractures. Along with stimulating physical puberty by achieving virilization and a normal muscle mass and improving psychosocial wellbeing, the goals of testosterone replacement therapy in male hypogonadism also include attainment of age-specific bone mineral density. We report on a 37-year-old man who presented with multiple vertebral compression fractures several years following termination of testosterone replacement therapy for presumed constitutional delay in growth and puberty. Here, we discuss the management of congenital hypogonadotropic hypogonadism with hyposmia (Kallmann syndrome), with which the patient was ultimately diagnosed, the role of androgens in the acquisition of bone mass during puberty and its maintenance thereafter, and outline specific management strategies for patients with hypogonadism and high risk for fragility fractures.

Sign in / Sign up

Export Citation Format

Share Document